Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Optiscan Imaging Limited ( (AU:OIL) ) has issued an announcement.
Optiscan Imaging reported a 43% drop in half-year revenue to $339,227, driven largely by weaker sales of its ViewnVivo life sciences research device amid constrained research funding in the U.S. and China. The company’s net loss widened to $3.4 million as R&D and intellectual property expenses rose to $2.66 million, reflecting continued investment to advance multiple technology applications and prepare clinical studies for FDA submissions.
Other income fell due to lower R&D incentive receipts and the absence of prior-period grant funding, while operating cash outflows increased modestly to $4.13 million. However, Optiscan’s balance sheet strengthened significantly, with net assets rising to $22 million and cash increasing by $13.2 million, after a $17.8 million fully underwritten entitlement offer to fund clinical studies, regulatory work and progress on its flexible endomicroscope program.
More about Optiscan Imaging Limited
Optiscan Imaging Limited is a medical imaging technology company that develops and markets confocal endomicroscopy systems, including its ViewnVivo device for life sciences research. The company focuses on clinical medical devices and flexible endomicroscope solutions, targeting applications that require real-time, high-resolution imaging in research and healthcare markets.
Average Trading Volume: 155,395
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$89.8M
For a thorough assessment of OIL stock, go to TipRanks’ Stock Analysis page.